The Bull Rankings scorecard — our quality-growth score is 66.2 / 100, built from three pillars scored 0–100: Quality 47, Growth 100, Value 62 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 59% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
The market has priced a high-wire act into Arcutis Biotherapeutics, and the numbers make the bet worth examining—if you believe the growth can last. Our model gives ARQT a 66.2/100 quality-growth score, with Growth at 100 and Quality at 47, which tells you everything: the upside is all about the top line, not the balance sheet. Revenue grew 76.1% year-over-year in the fiscal year ending in the quarter ended 2026-06-30, a figure so strong it makes the 108.1 P/E look almost reasonable. The PEG ratio of 0.5 suggests the growth is cheap relative to earnings, but that’s only true if the growth doesn’t stall. The weakest pillar—Quality at 47—is the caution flag: 6.1% profit margins and 12.9% ROE aren’t the kind of returns that survive a misstep. The stock’s $3.0 billion market cap and $39 million in trailing free cash flow mean there’s no margin for error. The bet is binary: either ZORYVE’s commercial ramp justifies the multiple, or the company burns through cash chasing the next indication.
What the business actually is
Arcutis isn’t a lab chasing a pipeline—it’s a dermatology company with a commercial product and a handful of shots on goal. The engine is ZORYVE, a topical roflumilast cream already approved for plaque psoriasis and atopic dermatitis, with foam formulations for seborrheic dermatitis and scalp/body psoriasis in the pipeline. The cream and foam are the revenue drivers today, targeting the dermatology market where patients and dermatologists alike are hungry for safer, steroid-free options. The company’s second asset, ARQ-234, a CD200 receptor agonist, is still preclinical, so for now, the entire growth story rides on ZORYVE’s commercial execution. Dermatology is a sticky market—once a patient and doctor settle on a treatment, switching is rare—which gives Arcutis a pricing power advantage if the data holds up. The question isn’t whether the products work; it’s whether the market will pay for them at scale.
Why it can (or can't) keep compounding
The durability case hinges on whether Arcutis can turn ZORYVE into a franchise before the patents expire or competitors crowd the space. Our model flags diluting shareholders as a concern, which means the company is likely tapping equity to fund commercial build-out—a red flag if the return on those shares doesn’t materialize. The 12.9% ROE isn’t terrible for a growth biotech, but it’s not the kind of fortress-like return that compounds for decades. The moat isn’t in the molecule; it’s in the formulary wins and the dermatologist relationships that lock in repeat prescriptions. If ZORYVE becomes the go-to non-steroidal for mild-to-moderate psoriasis, the compounding potential is real. But if insurers push back or biosimilars emerge, the margins could erode fast. The 6.1% profit margin in the latest quarter shows the business isn’t yet efficient enough to self-fund growth, which is why the $39 million in free cash flow feels more like a rounding error than a war chest. The company’s progress depends on ZORYVE’s uptake outpacing its spending.
The valuation question
The price isn’t cheap, but it’s not irrational—if you believe the growth can last. Our model’s reverse-DCF says today’s $23.78 implies 59% annual free-cash-flow growth (in year one, slowing to 3% a year by year ten), a starting rate below the 76.1% revenue growth in the latest year. That still assumes ZORYVE keeps winning share quickly. The P/E of 108.1 looks rich until you remember the PEG is 0.5, which is the market’s way of acknowledging the growth is real but volatile. The analyst consensus isn’t shy—$36.88 is the 12-month target, with a range of $34 to $40, implying 55% upside from here. But that’s predicated on ZORYVE’s commercial momentum continuing unabated. If the growth slows, the multiple would need to compress hard to justify the price. The valuation is a bet on execution, not a bargain.
The bear case
The biggest red flag is the dilution risk. Our model explicitly calls it out, and the recent insider moves don’t help. In late August, board member Terrie Curran exercised options and sold shares, a move that, while routine, sends a signal that insiders are taking chips off the table. More concerning, another insider planned a $956,000 share sale around the same time, which chips away at the bull thesis that the stock is a steal. The debt-to-equity ratio of 0.52 isn’t a crisis, but it’s a reminder that Arcutis isn’t self-funding its growth. If ZORYVE’s uptake stalls, the company will either need to raise more money at a lower price or cut spending, which would crater the growth story. The beta of 1.53 means the stock will amplify any market downdraft, and with a week 52 high of $31.77, the downside to the low of $15.13 is brutal if the growth narrative cracks. The bear case isn’t that ZORYVE fails—it’s that the market realizes the growth isn’t as durable as priced in.
What would change our mind
Three things would flip the thesis. First, profit margins breaking above 15%—today’s 6.1% is a warning that the business isn’t yet efficient enough to justify the multiple. Second, free cash flow turning positive and growing at a steady clip—the $39 million in trailing cash flow needs to compound, not stagnate. Third, ZORYVE securing formulary wins in Europe or Japan, where the addressable market is larger and less crowded. If any of these happen, the quality pillar would strengthen, the PEG would look less aggressive, and the reverse-DCF’s implied growth would start to feel achievable. Until then, the stock is a high-beta lottery ticket on dermatology’s next blockbuster.